| Name |
Trial sites |
Immunogen |
Targeted immune response |
Efficacy |
References |
| VAX004 |
USA, Canada, Netherlands |
AIDSVAX B/B gp120 |
CD4+ T cells, antibodies |
No efficacy |
5 |
| VAX003 |
Thailand |
AIDSVAX B/E gp120 |
CD4+ T cells, antibodies |
No efficac |
6 |
STEP Study
(HVTN502) |
USA, Canada, Latin America |
MRKAd5 HIV-1 gag/pol/nef B |
CD4+ T cells, CD8+ T cells |
No efficacy |
7 |
Phambili trial
(HVTN503) |
SouthAfrica |
MRKAd5 HIV-1 gag/pol/nef B |
CD4+ T cells, CD8+ T cells |
No efficacy |
8 |
| RV144 |
Thailand |
ALVAC-HIV vCP1521 and
AIDSVAX B/E rgp120 |
CD4+ T cells, CD8+ T cells, antibodies |
31.2% efficacy |
9 |
|
